TransCelerate's preclinical move into toxicology
Building on its efforts to improve and accelerate clinical trials, TransCelerate BioPharma Inc. has created a subsidiary consortium, BioCelerate, to tackle industry-wide challenges in the preclinical space. However, the new consortium is starting out slower than its parent, with only six members and a single project, limited to sharing tox data, as the partners try to carve out other areas of safe terrain for precompetitive collaboration.
BioCelerate is keeping its finances separate from TransCelerate, but is built with the same not-for-profit model, and is likewise funded by its members: Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co., Eli Lilly and Co., GlaxoSmithKline plc, Novo Nordisk A/S and Shionogi & Co. Ltd. Financial details and membership fees haven't been disclosed.
In 2012, TransCelerate was formed by 10 partners and focused on five projects that would accelerate drug development or reduce costs for individual companies.
By August 2013, the consortium had met its one-year goals in all five areas and grown to 18 partner companies. Now there are 19 companies and 16 projects, all in the clinical space.
CEO Dalvir Gill told BioCentury that while TransCelerate's remit spans R&D, it decided from the outset to focus on improving clinical trials because that seemed to be the area where companies would be most amenable to precompetitive collaboration, given the industry's needs.
But they've long been discussing how to extend the model to other areas, said Gill.